119th Congress · introduced in the House · Mar 5, 2026
Medicines for the People Act
Official title from Congress.gov
Latest action (Mar 5, 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
4 citations.
P STREET PROJECT, INC. · lobbying firm or registrant: P STREET PROJECT, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$10,000
Spent on own lobbying
Lobbied in support of universal health care, including the Medicare for All Act (H.R. 3069) and the Medicines for the People Act (H.R. 7854). Lobbied in support of reforms to Medicare Advantage, including H.R 9544, and in support of universal health care.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
P STREET PROJECT, INC. · lobbying firm or registrant: P STREET PROJECT, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Pharmacy
$10,000
Spent on own lobbying
Lobbied in support of public manufacturing of prescription drugs (H.R.7854 - Medicines for the People Act).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
T1INTERNATIONAL USA · lobbying firm or registrant: T1INTERNATIONAL USA
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
Amount not reported
…anufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
P STREET PROJECT, INC. · lobbying firm or registrant: P STREET PROJECT, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Pharmacy
$10,000
Spent on own lobbying
Lobbied in support of a public option for Pharmaceuticals (H.R.7854 - Medicines for the People Act).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing